Ipsen delivers strong sales in the first quarter of 2026 and confirms its full-year guidance
Ojemda® approved in the European Union as the first targeted therapy in relapsed or refractory pediatric low-grade glioma regardless of...
Ipsen announces that Beech Tree has obtained an exemption from the obligation to submit a public tender offer
Ipsen showcases transformative potential of early immuno-oncology pipeline at AACR
Ipsen appoints Michelle C. Werner as EVP, President of North America
Ipsen voluntarily withdraws Tazverik® (tazemetostat) in follicular lymphoma and epithelioid sarcoma
Ipsen receives positive CHMP opinion for Ojemda® for the treatment as monotherapy of children with relapsed or refractory BRAF-altered pediatric...
Ipsen delivers strong results in 2025, driven by solid execution across all therapeutic areas, and provides 2026 guidance
Ipsen nominates Peter Guenter to its Board of Directors
Pierrick Lefranc appointed as Executive Vice President Technical Operations, member of Executive Leadership Team
You are now leaving the Ipsen group global website. To continue, please click on Continue?
